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Background
Critically ill patients often require emergency intubation. 
Th e use of etomidate as the sedative agent in this context 
has been challenged because it may cause a reversible 
adrenal insuﬃ  ciency, potentially associated with 
increased in-hospital morbidity. We compared early and 
28-day morbidity after a single dose of etomidate or 
ketamine used for emergency endotracheal intubation of 
critically ill patients.
Methods
In this randomized, controlled, single-blind trial, 655 
patients who needed sedation for emergency intubation 
were prospectively enrolled from 12 emergency medical 
services or emergency departments and 65 intensive care 
units in France. Patients were randomly assigned by a 
computerized random-number generator list to receive 
0·3 mg/kg of etomidate (n = 328) or 2 mg/kg of ketamine 
(n  =  327) for intubation. Only the emergency physician 
enrolling patients was aware of group assignment. Th e 
primary endpoint was the maximum score of the 
sequential organ failure assessment during the ﬁ rst 3 days 
in the intensive care unit. We excluded from the analysis 
patients who died before reaching the hospital or those 
discharged from the intensive care unit before 3  days 
(modiﬁ ed intention to treat). Th is trial is registered with 
ClinicalTrials.gov, number NCT00440102.
Findings
234 patients were analyzed in the etomidate group and 
235 in the ketamine group. Th e mean maximum SOFA 
score between the two groups did not diﬀ er signiﬁ cantly 
(10.3 [SD 3.7] for etomidate vs. 9.6 [3.9] for ketamine; 
mean diﬀ erence 0.7 [95% CI 0.0-1.4], p  =  0.056). Intu-
bation conditions did not diﬀ er signiﬁ cantly between the 
two groups (median intubation diﬃ  culty score 1 [IQR 
0-3] in both groups; p = 0.70). Th e percentage of patients 
with adrenal insuﬃ  ciency was signiﬁ cantly higher in the 
etomidate group than in the ketamine group (OR 6.7, 
3.5-12.7). We recorded no serious adverse events with 
either study drug.
Interpretation
Our results show that ketamine is a safe and valuable 
alternative to etomidate for endotracheal intubation in 
critically ill patients, and should be considered in those 
with sepsis.
Commentary
A single dose of etomidate is associated with decreased 
serum concentrations of cortisol for at least 24 hours 
after its administration [1,2]. Continuous intravenous 
adminis tration of etomidate has been associated with 
adreno cortical dysfunction and increased patient mor-
tality [3-5]. Several studies have suggested an association 
between etomidate-induced adrenal insuﬃ  ciency and 
increased morbidity in the critically ill, particularly in 
those with sepsis [6,7]. Yet, etomidate continues to be 
used commonly for rapid sequence intubation as it is less 
likely to cause hypotension. Th is favorable cardiovascular 
proﬁ le is important in critically ill patients with severe 
sepsis. Th is study was designed to investigate the possi-
bility of a causal relationship between etomodiate use 
and increased morbidity or mortality. Etomidate was 
compared to ketamine, which has similar cardiovascular 
proﬁ le, but may be associated with adverse psychiatric 
events [8].
Jabre et al. conducted a prospective, randomized 
controlled single-blind trial where subjects requiring 
intubation were randomized to etomidate (0.3 mg/kg) or 
ketamine (2  mg/kg) with succinylcholine prior to ICU © 2010 BioMed Central Ltd
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admission. Th e primary endpoint was the maximum 
score of the sequential organ failure assessment during 
the ﬁ rst 3 days in the intensive care unit. Secondary 
endpoints were identiﬁ ed as organ dysfunction and 
failure occurring after admission to the intensive care 
unit (Δ-SOFA), 28-day all-cause mortality, days free from 
intensive care unit, organ support-free days, and 
measure ment and correlation with adrenal insuﬃ  ciency. 
A modiﬁ ed intention-to-treat (ITT) analysis was used, 
where randomized patients who died before reaching 
hospital and those discharged from the intensive care 
unit within 3 days were excluded. Th is analysis adjusted 
for age, simpliﬁ ed acute physiology score II, and sex to 
ensure that these factors were equally distributed 
between these groups because the modiﬁ ed ITT analysis 
was performed in 469 of the 655 subjects who were 
randomized.
Th e results did not demonstrate any signiﬁ cant diﬀ er-
ences in mean SOFAmax score, 28-day mortality, catechol-
amine use, median ventilator-free days, and median 
hospital-free days between the two groups. Since the 
investigators had speciﬁ c concerns for patients with 
severe sepsis or trauma, these populations were identiﬁ ed 
as subgroups of interest a priori; however, no signiﬁ cant 
diﬀ erences in maximum SOFA were seen. Th e investi-
gators did ﬁ nd that the percentage of patients with adrenal 
insuﬃ  ciency was signiﬁ cantly higher in the etomidate 
group (86% vs. 48%, p < 0.0001). However, no signiﬁ cant 
diﬀ erences in morbidity or mortality were found in those 
with adrenal insuﬃ  ciency. Th e authors concluded that 
ketamine is a safe and valuable alternative to etomidate 
and should be considered in those with sepsis. Th is 
recommendation seems to be derived from the post hoc 
analysis of CORTICUS trial [9] suggesting that patients 
with severe sepsis had a signiﬁ cantly higher 28-day 
mortality rate if they received etomidate (p = 0·03).
Th e strength of this study is the randomized controlled 
prospective design. Randomization in the modiﬁ ed 
intention to treat analysis appeared to be complete. It 
adds to the body of literature suggesting that a single 
dose of etomidate may be associated with adrenal 
insuﬃ  ciency but is not associated with an increase in 
morbidity or mortality. Th e weakness of the study is that 
the design was underpowered to detect diﬀ erences in the 
subgroups of interest (patients with trauma and sepsis, 
n = 180) and it was also underpowered to detect diﬀ er-
ences in mortality. Th is study may not be generalizable to 
inpatients requiring emergent intubation as this study 
was conducted in the pre-hospital and emergency 
department setting, where the majority of intubations 
were performed for “comatose” patients.
In conclusion, this study found no diﬀ erence in early 
and 28-day morbidity and mortality after a single dose of 
etomidate or ketamine used for emergency endotracheal 
intubation of critically ill patients. Th is study was unable 
to answer questions about the impact of etomidate and 
its related adrenal insuﬃ  ciency on trauma and sepsis 
populations and larger randomized controlled trials will 
be needed.
Recommendations
One bolus of etomidate is not associated with a 
signiﬁ cant increase in morbidity or mortality compared 
to ketamine. Etomidate can still be safely be used for 
rapid sequence intubation.
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